Identification of neoantigens and development of antigen-specific immunotherapy

DOI Web Site PubMed

Bibliographic Information

Other Title
  • ネオ抗原の同定と抗原特異的免疫療法の開発
  • ネオ コウゲン ノ ドウテイ ト コウゲン トクイテキ メンエキ リョウホウ ノ カイハツ

Search this article

Abstract

<p>Cancer cells harboring somatic mutations give rise to neoantigens, which are immunologically foreign in nature to be distinguished from itself, showing high immunogenicity and, thus, induce specific T-cell responses against cancer. Therefore, neoantigens are expected to be promising targets for anti-cancer immunotherapy. The general methods used to identify candidate neoantigens are as follows: (1) non-synonymous mutations are identified by whole exome and RNA sequencing; (2) neoantigens from the mutations are predicted based on in silico MHC ligand prediction algorithm; (3) specific T-cell responses toward the candidate neoantigens are verified using tumor infiltrating T cells or peripheral blood mononuclear cells. In hematological malignancy, several neoantigens have been identified as an important treatment target. In contrast with solid malignancies, the occurrence of frameshift mutations and fusion genes producing neoantigens are high. A shared neoantigen derived from frameshift mutation of nucleophosmin I, which is often observed in acute myeloid leukemia, was reported to induce specific immune responses in vitro and in vivo. We should examine neoantigens as possible target of novel immunotherapy despite several issues to be addressed for clinical application.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 61 (9), 1433-1439, 2020

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top